NZ504066A - Vaginal delivery of progestin to promote regular withdrawal bleeding - Google Patents
Vaginal delivery of progestin to promote regular withdrawal bleedingInfo
- Publication number
- NZ504066A NZ504066A NZ504066A NZ50406698A NZ504066A NZ 504066 A NZ504066 A NZ 504066A NZ 504066 A NZ504066 A NZ 504066A NZ 50406698 A NZ50406698 A NZ 50406698A NZ 504066 A NZ504066 A NZ 504066A
- Authority
- NZ
- New Zealand
- Prior art keywords
- progestin
- vaginal delivery
- withdrawal bleeding
- regular withdrawal
- promote regular
- Prior art date
Links
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 title abstract 4
- 239000000583 progesterone congener Substances 0.000 title abstract 4
- 208000034423 Delivery Diseases 0.000 title abstract 2
- 230000009677 vaginal delivery Effects 0.000 title abstract 2
- 206010047998 Withdrawal bleed Diseases 0.000 title 1
- 201000000736 Amenorrhea Diseases 0.000 abstract 1
- 206010001928 Amenorrhoea Diseases 0.000 abstract 1
- 206010051909 Endometrial atrophy Diseases 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 231100000540 amenorrhea Toxicity 0.000 abstract 1
- 230000000740 bleeding effect Effects 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 238000012377 drug delivery Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000004696 endometrium Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 230000003248 secreting effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6348597P | 1997-10-21 | 1997-10-21 | |
| US09/170,326 US6306914B1 (en) | 1997-10-21 | 1998-10-13 | Progestin therapy for maintaining amenorrhea |
| PCT/US1998/022169 WO1999020282A1 (en) | 1997-10-21 | 1998-10-21 | Progestin therapy with controlled bleeding |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ504066A true NZ504066A (en) | 2002-11-26 |
Family
ID=26743461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ504066A NZ504066A (en) | 1997-10-21 | 1998-10-21 | Vaginal delivery of progestin to promote regular withdrawal bleeding |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US6306914B1 (enExample) |
| EP (1) | EP1032399A1 (enExample) |
| JP (1) | JP2003535015A (enExample) |
| KR (1) | KR100581308B1 (enExample) |
| CN (1) | CN1147301C (enExample) |
| AR (1) | AR013981A1 (enExample) |
| AU (1) | AU742166C (enExample) |
| BR (1) | BR9813262A (enExample) |
| CA (2) | CA2307615A1 (enExample) |
| HU (1) | HUP0004133A3 (enExample) |
| IL (1) | IL135742A (enExample) |
| MX (1) | MXPA00003972A (enExample) |
| MY (1) | MY121743A (enExample) |
| NO (1) | NO326856B1 (enExample) |
| NZ (1) | NZ504066A (enExample) |
| PE (1) | PE121799A1 (enExample) |
| RO (1) | RO121319B1 (enExample) |
| RU (2) | RU2261099C2 (enExample) |
| WO (1) | WO1999020282A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL127129A (en) * | 1998-11-18 | 2004-06-01 | Ferring Bv | Method for preparation of progesterone tablets for vaginal delivery and tablets so prepared |
| US20040191276A1 (en) * | 1999-11-30 | 2004-09-30 | Cutispharma, Inc. | Compositions and kits for compounding pharmaceuticals |
| US8425892B2 (en) * | 2001-10-29 | 2013-04-23 | Columbia Laboratories, Inc. | Extended, controlled-release pharmaceutical compositions using charged polymers |
| ES2561491T3 (es) * | 2001-12-05 | 2016-02-26 | Teva Women's Health, Inc. | Anticonceptivos orales para prevenir el embarazo |
| CA2496618A1 (en) * | 2002-05-23 | 2003-12-04 | Michael Holick | Use of a parathyroid hormone peptide analogs for the treatment of vaginal atrophy |
| AU2003297534A1 (en) * | 2002-12-24 | 2004-07-22 | Ovion, Inc. | Contraceptive device and delivery system |
| CA2524474A1 (en) * | 2003-05-02 | 2004-11-18 | Duramed Pharmaceuticals, Inc. | Methods of hormonal treatment utilizing extended cycle contraceptive regimens |
| SI1635843T1 (sl) * | 2003-06-25 | 2009-06-30 | Bayer Schering Pharma Ag | Terapija, ki vsebuje dienogest, za hormonsko nadomestitev in depresijo |
| JP2007534622A (ja) * | 2003-07-16 | 2007-11-29 | デュラメド ファーマシューティカルズ インコーポレーティッド | 連続的エストロゲン投与での避妊薬療法を利用するホルモン処置の方法 |
| EP1761231A1 (en) * | 2004-06-07 | 2007-03-14 | Duramed Pharmaceuticals, Inc. | Dispenser for progestin used for acute and maintenance treatment of dub |
| US20070111975A1 (en) | 2004-10-07 | 2007-05-17 | Duramed Pharmaceuticals, Inc. | Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens |
| JP2009521533A (ja) * | 2005-12-27 | 2009-06-04 | デュラメド ファーマシューティカルズ インコーポレーティッド | 結合型エストロゲン組成物、アプリケーター、キット、ならびにそれらの作製および使用の方法 |
| CA2637608A1 (en) * | 2006-01-20 | 2007-07-26 | Pear Tree Pharmaceuticals, Inc. | Method of treating atrophic vaginitis |
| US8235047B2 (en) | 2006-03-30 | 2012-08-07 | Conceptus, Inc. | Methods and devices for deployment into a lumen |
| CA2654152A1 (en) * | 2006-06-02 | 2007-12-13 | Pear Tree Women's Health Care | Method of treating atrophic vaginitis |
| GB0616444D0 (en) * | 2006-08-18 | 2006-09-27 | Reckitt Benckiser Nv | Detergent composition |
| WO2008091592A1 (en) | 2007-01-22 | 2008-07-31 | Targacept, Inc. | Intranasal, buccal, and sublingual administration of metanicotine analogs |
| US8828981B2 (en) | 2007-02-06 | 2014-09-09 | George Creasy | Progesterone for the treatment or prevention of spontaneous preterm birth |
| MX337634B (es) | 2008-02-04 | 2016-03-14 | Teva Womens Health Inc | Anillos intravaginales monoliticos que comprenden progesterona y metodos de manufactura y uso de los mismos. |
| BR112014012444B1 (pt) | 2011-11-23 | 2021-12-14 | Therapeuticsmd, Inc | Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| RU2016143081A (ru) | 2014-05-22 | 2018-06-26 | Терапьютиксмд, Инк. | Натуральные комбинированные гормонозаместительные составы и терапии |
| AU2015296609A1 (en) | 2014-07-29 | 2016-12-22 | Therapeuticsmd, Inc. | Transdermal cream |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| KR20180126582A (ko) | 2016-04-01 | 2018-11-27 | 쎄러퓨틱스엠디, 인코퍼레이티드 | 스테로이드 호르몬 약제학적 조성물 |
| WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
| RU2697369C1 (ru) * | 2018-12-21 | 2019-08-13 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской | Способ дифференциальной диагностики функциональной гипоталамической аменореи на фоне стресса и энергетического дефицита |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
| CN113288865B (zh) * | 2021-06-28 | 2022-03-08 | 浙江仙琚制药股份有限公司 | 一种黄体酮阴道凝胶剂的制备方法 |
| CN114983929A (zh) * | 2022-05-16 | 2022-09-02 | 安徽万邦医药科技股份有限公司 | 一种稳定的黄体酮缓释凝胶及其制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0501523B1 (en) | 1983-11-14 | 1997-04-09 | Columbia Laboratories, Inc. | Bioadhesive compositions |
| USD345211S (en) | 1992-04-06 | 1994-03-15 | Columbia Laboratories, Inc. | Dispensing vial for feminine hygiene products |
| US5543150A (en) * | 1993-09-15 | 1996-08-06 | Columbia Laboratories, Inc. | Method of progesterone delivery and affect thereof |
| USD375352S (en) | 1994-03-14 | 1996-11-05 | Columbia Laboratories, Inc. | Dispensing vial for feminine hygiene products |
-
1998
- 1998-10-13 US US09/170,326 patent/US6306914B1/en not_active Expired - Fee Related
- 1998-10-21 MX MXPA00003972A patent/MXPA00003972A/es not_active IP Right Cessation
- 1998-10-21 HU HU0004133A patent/HUP0004133A3/hu unknown
- 1998-10-21 AU AU11914/99A patent/AU742166C/en not_active Ceased
- 1998-10-21 CN CNB988123894A patent/CN1147301C/zh not_active Expired - Fee Related
- 1998-10-21 RU RU2000112650/14A patent/RU2261099C2/ru not_active IP Right Cessation
- 1998-10-21 NZ NZ504066A patent/NZ504066A/xx unknown
- 1998-10-21 JP JP2000516679A patent/JP2003535015A/ja active Pending
- 1998-10-21 BR BR9813262-8A patent/BR9813262A/pt not_active Application Discontinuation
- 1998-10-21 EP EP98955011A patent/EP1032399A1/en not_active Withdrawn
- 1998-10-21 PE PE1998000990A patent/PE121799A1/es not_active Application Discontinuation
- 1998-10-21 CA CA002307615A patent/CA2307615A1/en not_active Abandoned
- 1998-10-21 WO PCT/US1998/022169 patent/WO1999020282A1/en not_active Ceased
- 1998-10-21 KR KR1020007004288A patent/KR100581308B1/ko not_active Expired - Fee Related
- 1998-10-21 RO ROA200000428A patent/RO121319B1/ro unknown
- 1998-10-21 IL IL13574298A patent/IL135742A/en not_active IP Right Cessation
- 1998-10-21 CA CA002649671A patent/CA2649671A1/en not_active Abandoned
- 1998-10-21 MY MYPI98004790A patent/MY121743A/en unknown
- 1998-10-22 AR ARP980105256A patent/AR013981A1/es unknown
-
2000
- 2000-04-19 NO NO20002084A patent/NO326856B1/no not_active IP Right Cessation
- 2000-10-17 US US09/833,259 patent/US6593317B1/en not_active Expired - Fee Related
-
2001
- 2001-04-03 US US09/825,569 patent/US20010031747A1/en active Pending
-
2005
- 2005-01-21 RU RU2005101612/14A patent/RU2330667C2/ru not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR100581308B1 (ko) | 2006-05-22 |
| IL135742A0 (en) | 2001-05-20 |
| AR013981A1 (es) | 2001-01-31 |
| CA2307615A1 (en) | 1999-04-29 |
| MY121743A (en) | 2006-02-28 |
| RU2005101612A (ru) | 2006-07-10 |
| AU1191499A (en) | 1999-05-10 |
| US6306914B1 (en) | 2001-10-23 |
| NO326856B1 (no) | 2009-03-02 |
| AU742166B2 (en) | 2001-12-20 |
| AU742166C (en) | 2005-07-14 |
| EP1032399A1 (en) | 2000-09-06 |
| PE121799A1 (es) | 1999-12-17 |
| BR9813262A (pt) | 2000-08-22 |
| US20010031747A1 (en) | 2001-10-18 |
| RO121319B1 (ro) | 2007-03-30 |
| CN1147301C (zh) | 2004-04-28 |
| RU2330667C2 (ru) | 2008-08-10 |
| WO1999020282A1 (en) | 1999-04-29 |
| RU2261099C2 (ru) | 2005-09-27 |
| NO20002084L (no) | 2000-06-21 |
| JP2003535015A (ja) | 2003-11-25 |
| US6593317B1 (en) | 2003-07-15 |
| IL135742A (en) | 2004-09-27 |
| KR20010031299A (ko) | 2001-04-16 |
| HUP0004133A3 (en) | 2001-09-28 |
| NO20002084D0 (no) | 2000-04-19 |
| MXPA00003972A (es) | 2004-04-21 |
| HUP0004133A2 (hu) | 2001-05-28 |
| CA2649671A1 (en) | 1999-04-29 |
| CN1282250A (zh) | 2001-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ504066A (en) | Vaginal delivery of progestin to promote regular withdrawal bleeding | |
| US5543150A (en) | Method of progesterone delivery and affect thereof | |
| RU2000112650A (ru) | Прогестинотерапия с регулируемым кровотечением | |
| JP3314207B2 (ja) | ホルモン製剤及び方法 | |
| NZ504668A (en) | Methods for treating postmenopausal women using ultra-low doses of estrogen | |
| DE68928897D1 (de) | Verfahren und system zur empfängnisverhütung | |
| BG100940A (en) | Combined hormonal contraception pharmaceutical preparation | |
| DK0836506T3 (da) | Transdermalt plaster til indgivelse af 17-deacetyl norgestimat alene eller i kombination med et østrogen | |
| AU7537987A (en) | Combination dosage form for pre-menopausal women | |
| AU6821687A (en) | System for delivering drug with enhanced bioacceptability | |
| SIMPSON et al. | Induction of ovulation with human urinary gonadotrophins in the monkey | |
| AU3869695A (en) | Competitive progesterone antagonists for demand-oriented female birth control | |
| GEP20043253B (en) | Progestin Therapy with Controlled Bleeding | |
| Smith et al. | Inhibitory action of oestrogen on calcium-induced mitosis in rat bone marrow and thymus | |
| Swahn et al. | 5 Medical methods to terminate early pregnancy | |
| Abdalla et al. | Organon OD 14 (tibolone) and menopausal dynamic hormone profiles | |
| AU689133C (en) | Novel method of progesterone delivery and affect thereof | |
| Pongsatha et al. | Morning and evening administration of hormone therapy in perimenopausal women | |
| Lemay et al. | Intermittent LHRH agonist sequentially combined with a progestogen as antiovulatory contraception | |
| Miller et al. | Lipid and lipoprotein changes due to estrogen replacement therapies and their association with prevention of cardiovascular disease in postmenopausal women | |
| UA19520A (uk) | Спосіб дородової підготовки шийки матки | |
| Mehdi I et al. | Reduction of experimentally induced endometrial hyperplasia by atenolol | |
| Nachtigall | Postmenopausal Women | |
| UA31211A (uk) | Спосіб специфічної профілактики резус-конфлікту |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENW | Renewal (renewal fees accepted) | ||
| S38A | Application for proceedings under section 38 (amendment of specification with leave of commissioner) |
Free format text: BY WAY OF CORRECTION |
|
| PSEA | Patent sealed | ||
| S38C | Proceedings under section 38 (amendment of specification with leave of commissioner): specification amended | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |